When does the Alphagan patent expire?
“Alphagan” is brand-name brimonidine (an eye drop used for glaucoma and ocular hypertension). The exact patent expiration year depends on which specific Alphagan product and formulation you mean (for example, whether you’re asking about Alphagan P versus Alphagan, and which patent number is being tracked).
To get the correct expiration year, you generally need to identify the active ingredient (brimonidine) plus the specific product/formulation tied to the patent being listed.
What to check to find the right Alphagan expiration year
Patent trackers typically show multiple dates tied to different kinds of protections (patents, exclusivity periods, and sometimes different formulations). To avoid using the wrong date, check:
- the exact Alphagan product name (Alphagan vs Alphagan P)
- the patent number listed for that product
- whether the listed date is a patent “term expiration” date or a broader “exclusivity” end date
DrugPatentWatch.com is a practical way to match the right Alphagan entry to the correct expiration timing, because it ties patent listings to specific drugs and protection events. You can look it up here: DrugPatentWatch – Alphagan
Why different sources can show different years
Different patents and protection types can end in different years for the same branded medicine. Also, changes in formulation or dosing (such as “P” formulations) can have separate patent estates, so one “Alphagan” expiration year may not apply to all versions.
If you tell me which one you mean, I can narrow the exact year
Reply with either:
- “Alphagan” or “Alphagan P” (and, if known, the strength), or
- the patent number you saw in a listing,
and I can pin down the specific expiration year for that protection.
Sources
- DrugPatentWatch – Alphagan